The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/-Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

被引：25
|
作者：
Serrano, Dolores [1 ]
Torrado, Susana [1 ]
Torrado-Santiago, Santiago [1 ]
Gisbert, Javier P. [2 ]
机构：
[1] Univ Complutense, Fac Farm, Dept Pharmaceut Technol, E-28040 Madrid, Spain
[2] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IP, Dept Gastroenterol, Madrid, Spain
来源：
CURRENT DRUG METABOLISM | 2012年 / 13卷 / 09期
关键词：
CYP2C19; genetic polymorphism; Helicobacter pylori eradication; proton pump inhibitor; rabeprazole; omeprazole; lansoprazole; pantoprazole; esomeprazole; CYTOCHROME-P450; ENZYMES; 2C9; 1-WEEK TRIPLE THERAPY; RANDOMIZED OPEN TRIAL; ERADICATION RATE; CURE RATES; OMEPRAZOLE METABOLISM; GENOTYPIC DIFFERENCES; DRUG-METABOLISM; DUAL THERAPY; RABEPRAZOLE;
D O I：
10.2174/138920012803341393
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism of individual PPIs to different extents. Although PPIs are highly effective as a class, differences in their pharmacokinetics, such as bioavailability and metabolism, may translate into differences in clinical outcomes. In Helicobacter pylori infection, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole but no with rabeprazole.
引用
收藏
页码：1303 / 1312
页数：10
相关论文
共 50 条
  • [21] Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
    Wang, JH
    Liu, ZQ
    Wang, W
    Chen, XP
    Shu, Y
    He, N
    Zhou, HH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (01) : 42 - 47
  • [22] Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori
    Lin, Yun-An
    Wang, Hong
    Gu, Zhu-Jun
    Wang, Wen-Jia
    Zeng, Xiao-Yan
    Du, Yan-Lei
    Ying, Song-Song
    Zhang, Bo-Hua
    MEDICAL SCIENCE MONITOR, 2017, 23 : 2701 - 2707
  • [23] Effect of genetic differences in (CYP2C19) on cure rates for Helicobacter pylori infection by a triple therapy with proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta, T
    Shirai, N
    Takashima, M
    Xiao, F
    Hanai, H
    Ohashi, K
    Ishizaki, T
    GASTROENTEROLOGY, 2000, 118 (04) : A496 - A496
  • [24] The influence of CYP2C19 polymorphism on the eradication of Helicobacter pylori:: A randomized study of lansoprazole and rabeprazole
    Jung, H. Y.
    Song, H. J.
    Choi, K. D.
    Chung, J. W.
    Kim, D. H.
    Kim, J. H.
    HELICOBACTER, 2007, 12 (04) : 429 - 429
  • [25] Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage
    Kang, Jung Mook
    Kim, Nayoung
    Lee, Dong Ho
    Park, Young Soo
    Kim, Joo Sung
    Chang, In Jin
    Song, In Sung
    Jung, Hyun Chae
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (08) : 1287 - 1291
  • [26] CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Shirai, Naohito
    Ishizaki, Takashi
    PHARMACOGENOMICS, 2007, 8 (09) : 1199 - 1210
  • [27] Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis
    Zhao, Fujun
    Wang, Jing
    Yang, Yanmei
    Wang, Xiaoyong
    Shi, Ruihua
    Xu, Zekuan
    Huang, Zuhu
    Zhang, Guoxin
    HELICOBACTER, 2008, 13 (06) : 532 - 541
  • [28] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    H. Katsuki
    C. Nakamura
    K. Arimori
    S. Fujiyama
    M. Nakano
    European Journal of Clinical Pharmacology, 1997, 52 : 391 - 396
  • [29] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    Katsuki, H
    Nakamura, C
    Arimori, K
    Fujiyama, S
    Nakano, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) : 391 - 396
  • [30] Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxicillin, and clarithromycin.
    Dojo, M
    Azuma, T
    Ohtani, M
    Muramatsu, A
    Suto, H
    Ito, Y
    Kuriyama, M
    GASTROENTEROLOGY, 2001, 120 (05) : A582 - A582
12345